Risk factor
Poor trading liquidity
Profitability factor
Greatly undervalued vs peers
About
Guerbet SA is dedicated to the development and commercialization of a broad spectrum of contrast media, advanced delivery systems, medical devices, and related solutions for diagnostic imaging. Their extensive product lineup features iodinated contrast agents such as Optiray and Xenetix, both non-ionic monomeric; Telebrix Gastro, a meglumine ioxitalamate solution; and Conray, an iothalamate meglumine injection. They also offer Micropaque/Microtrast, an integrated diagnostic imaging solution. For MRI applications, the company provides gadoteric acid-based contrast agents like Dotarem (gadoterate meglumine) and Artirem. Complementing these are essential delivery systems and consumables, including prefilled syringes, injectors, and accessories designed for use in MRI, CT, and Cath Lab settings. Guerbet also delivers innovative digital health solutions such as Contrast&Care for injection management, Dose&Care for X-ray dose management, and icobrain, a cloud-based AI platform that quantifies disease-specific brain structures from MR and CT scans for acute and chronic neurological conditions. Additionally, they offer OptiProtect services. In the realm of interventional radiology, the company provides products like Lipiodol (ethyl esters of iodinated fatty acids of poppyseed oil), Vectorio (a mixing and injection system for conventional trans-arterial chemoembolization), Patent Blue V (a blue dye), Axessio (a peripheral micro guidewire), and microcatheters such as SeQure and DraKon. Furthermore, their offerings include Hydra Vision, a digital imaging system tailored for urological, gastroenterological, and gynecological treatment, planning, and diagnostic procedures, alongside various urology accessories and consumables. Established in 1926, Guerbet's headquarters are situated in Villepinte, France.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITDA, underpriced
Target Price
The average target price of GBT.PA is 11.0 and suggests 23.7% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in